QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D-MUTATION KRAS PROTEIN

[Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. [Solution] The present inventors have examined a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer, and have found that...

Full description

Saved in:
Bibliographic Details
Main Authors MORIKAWA, Takahiro, KURAMOTO, Kazuyuki, IMADA, Sunao, WATANABE, Hideyuki, HAMAGUCHI, Hisao, ISHIOKA, Hiroki, KAWAMINAMI, Eiji, KAWAGUCHI, Kenichi, IMAIZUMI, Tomoyoshi, INAMURA, Kohei, OKUMURA, Mitsuaki, NAGASHIMA, Takeyuki, YOSHINARI, Tomohiro
Format Patent
LanguageEnglish
Published 21.09.2023
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:[Problem] To provide a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer. [Solution] The present inventors have examined a compound useful as an active ingredient of a pharmaceutical composition for treating pancreatic cancer, and have found that a quinazoline compound has an excellent activity of inducing the degradation of G12D-mutation KRAS protein and an activity of inhibiting a G12D-mutation KRAS, and can be used as a therapeutic agent for pancreatic cancer, thereby completing the present invention. The quinazoline compound or a salt thereof according to the present invention can be used as a therapeutic agent for pancreatic cancer.
Bibliography:Application Number: AU20220221145